Retatrutide Clinical Trial Results: Breaking Down the Phase 2 Data

The publication of the retatrutide Phase 2 trial in the New England Journal of Medicine marked a notable moment in obesity pharmacology research. With a headline result of approximately 24.2% mean body weight reduction at the highest dose tested, the data attracted significant attention from researchers studying incretin-based therapies. This article takes a detailed look at what the trial actually measured, how the dose cohorts performed, what the adverse event profile looked like, and what the dose-response shape suggests for the Phase 3 program.

Study Design Overview

The trial — Jastreboff AM et al., N Engl J Med 2023;389(6):514–526 — was a randomized, double-blind, placebo-controlled Phase 2 study. Participants were adults with obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity) without type 2 diabetes. The treatment duration was 48 weeks, with follow-up extending beyond that point for safety monitoring.

The study was designed to evaluate five cohorts:

• Placebo
• Retatrutide 1 mg weekly
• Retatrutide 4 mg weekly
• Retatrutide 8 mg weekly
• Retatrutide 12 mg weekly

Each active dose arm used a titration schedule to reach the target maintenance dose, a standard approach in GLP-1-class agents intended to reduce gastrointestinal side effects during initiation.

Weight Loss Outcomes by Dose Cohort

The dose-response relationship in this trial was one of its most important features. Results at week 48 showed a clear, escalating pattern of body weight reduction:

• Placebo: approximately 2.1% reduction
• 1 mg: approximately 8.7% reduction
• 4 mg: approximately 17.3% reduction
• 8 mg: approximately 22.8% reduction
• 12 mg: approximately 24.2% reduction

The incremental gains across dose steps — particularly the continued improvement from 8 mg to 12 mg — suggest the dose-response curve had not reached a plateau at the highest dose tested. This is an unusual and significant finding. Many pharmacological agents in this class show a flattening of the dose-response curve at higher doses, meaning the marginal benefit of each additional milligram diminishes. The apparent absence of that plateau in the retatrutide data was notable to researchers reviewing it.

What "No Plateau" Means for Phase 3

When a Phase 2 trial's highest dose arm still shows incremental improvement without plateau, it raises several questions for Phase 3 design:

• Is there a higher optimal dose? If the dose-response continues beyond 12 mg, Phase 3 investigators may test higher maintenance doses.
• Does longer duration change the shape? The Phase 2 ran 48 weeks. Phase 3 trials in obesity pharmacology commonly run 72 weeks or longer, which could reveal additional weight loss or, alternatively, a plateau that emerges over time.
• Is this signal durable? Phase 2 trials are not powered to assess long-term durability, cardiovascular safety, or effects in special populations — all of which become primary concerns in Phase 3 design.

Adverse Event Profile

The adverse event data was consistent with the known profile of GLP-1-class agents. The most commonly reported events were gastrointestinal in nature:

• Nausea: the most frequently reported adverse event across all active dose cohorts
• Vomiting: notably dose-dependent, with higher rates at 8 mg and 12 mg
• Diarrhea: similarly dose-dependent and most common during dose escalation periods
• Constipation: reported less frequently but observed across cohorts

The adverse events were predominantly mild-to-moderate in severity and most common during the titration phase, with rates declining once participants reached stable maintenance dosing. Discontinuation rates due to adverse events were higher in the upper dose cohorts compared to placebo, though the overall discontinuation rate was within ranges seen in comparable trials of GLP-1-class agents.

No new or unexpected safety signals were identified in the Phase 2 data. However, Phase 2 trials are not powered or designed to detect rare adverse events, long-term cardiovascular effects, or outcomes in populations not included in the enrollment criteria.

The Placebo-Adjusted Effect

Subtracting the placebo response (~2.1% weight reduction) from the 12 mg result (~24.2%) gives a placebo-adjusted estimate of approximately 22.1 percentage points of body weight reduction attributable to the drug. This is a large effect size by any historical comparison in the pharmacological weight loss literature.

For comparison, the STEP 1 trial of semaglutide 2.4 mg (Wilding et al., 2021, N Engl J Med) reported a placebo-adjusted weight loss of approximately 12.4 percentage points at 68 weeks. While these are cross-trial comparisons with inherent limitations, the magnitude of the difference is substantial enough that researchers have described the retatrutide Phase 2 data as exceeding prior expectations for the class.

Key Takeaways

• The Phase 2 trial enrolled five cohorts (placebo, 1 mg, 4 mg, 8 mg, 12 mg) over 48 weeks in adults with obesity without type 2 diabetes
• The 12 mg cohort achieved ~24.2% mean body weight reduction — the largest pharmacological result reported in the class at the time
• The dose-response showed no apparent plateau at 12 mg, a finding with significant implications for Phase 3 dose selection
• Adverse events were predominantly GI (nausea, vomiting, diarrhea), dose-dependent, and most common during titration
• Phase 2 data establishes proof of concept and safety signal — durability, cardiovascular outcomes, and rare adverse events require Phase 3 investigation